A Built-In CpG Adjuvant in RSV F Protein DNA Vaccine Drives a Th1 Polarized and Enhanced Protective Immune Response

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2018 Jan 19

PMID 29342954

Citations 13

Authors

Yao Ma

Yue-Ying Jiao

Yun-Zhou Yu

Nan Jiang

Ying Hua

Xiu-Juan Zhang

Yuan-Hui Fu

Xiang-Lei Peng

Yan-Peng Zheng

Larry J Anderson

Jin-Sheng He

Affiliations

Soon will be listed here.

Abstract

Human respiratory syncytial virus (RSV) is the most significant cause of acute lower respiratory infection in children. However, there is no licensed vaccine available. Here, we investigated the effect of five or 20 copies of C-Class of CpG ODN (CpG-C) motif incorporated into a plasmid DNA vaccine encoding RSV fusion (F) glycoprotein on the vaccine-induced immune response. The addition of CpG-C motif enhanced serum binding and virus-neutralizing antibody responses in BALB/c mice immunized with the DNA vaccines. Moreover, mice vaccinated with CpG-modified vaccines, especially with the higher 20 copies, resulted in an enhanced shift toward a Th1-biased antibody and T-cell response, a decrease in pulmonary pathology and virus replication, and a decrease in weight loss after RSV challenge. This study suggests that CpG-C motif, cloned into the backbone of DNA vaccine encoding RSV F glycoprotein, functions as a built-in adjuvant capable of improving the efficacy of DNA vaccine against RSV infection.

Citing Articles

Augmented immunogenicity of the HPV16 DNA vaccine via dual adjuvant approach: integration of CpG ODN into plasmid backbone and co-administration with IL-28B gene adjuvant.

Zhou Y, Zhang T, Wang Z, Xu X Virol J. 2025; 22(1):3.

PMID: 39780219 PMC: 11707914. DOI: 10.1186/s12985-024-02604-7.

Impact of influenza immune imprinting on immune responses to subsequent vaccinations in mice.

Ma Y, Dong C, Kim J, Zhu W, Wei L, Wang Y Vaccine. 2024; 46:126670.

PMID: 39731808 PMC: 11894583. DOI: 10.1016/j.vaccine.2024.126670.

Immune Responses and Protection Profiles in Mice Induced by Subunit Vaccine Candidates Based on the Extracellular Domain Antigen of Respiratory Syncytial Virus G Protein Combined with Different Adjuvants.

Han R, Wang T, Cheng X, Bing J, Li J, Deng Y Vaccines (Basel). 2024; 12(6).

PMID: 38932414 PMC: 11209252. DOI: 10.3390/vaccines12060686.

Immunization with a mucosal, post-fusion F/G protein-based polyanhydride nanovaccine protects neonatal calves against BRSV infection.

Maina T, Grego E, Broderick S, Sacco R, Narasimhan B, McGill J Front Immunol. 2023; 14:1186184.

PMID: 37359514 PMC: 10289034. DOI: 10.3389/fimmu.2023.1186184.

Editorial: Microorganisms and their derivatives for cancer therapy.

Zhang Y, Rodrigues L, Cao Z, Li J Front Bioeng Biotechnol. 2023; 11:1137341.

PMID: 36714005 PMC: 9880520. DOI: 10.3389/fbioe.2023.1137341.

References

Verthelyi D, Ishii K, Gursel M, Takeshita F, Klinman D . Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J Immunol. 2001; 166(4):2372-7. DOI: 10.4049/jimmunol.166.4.2372. View

Kim H, Canchola J, BRANDT C, Pyles G, Chanock R, Jensen K . Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969; 89(4):422-34. DOI: 10.1093/oxfordjournals.aje.a120955. View

Graham B, Henderson G, Tang Y, Lu X, Neuzil K, Colley D . Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol. 1993; 151(4):2032-40. View

Coban C, Ishii K, Gursel M, Klinman D, Kumar N . Effect of plasmid backbone modification by different human CpG motifs on the immunogenicity of DNA vaccine vectors. J Leukoc Biol. 2005; 78(3):647-55. DOI: 10.1189/jlb.1104627. View

Bode C, Zhao G, Steinhagen F, Kinjo T, Klinman D . CpG DNA as a vaccine adjuvant. Expert Rev Vaccines. 2011; 10(4):499-511. PMC: 3108434. DOI: 10.1586/erv.10.174. View

Li X, Sambhara S, Li C, Ettorre L, Switzer I, Cates G . Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate. Virology. 2000; 269(1):54-65. DOI: 10.1006/viro.2000.0186. View

Anderson L, Dormitzer P, Nokes D, Rappuoli R, Roca A, Graham B . Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine. 2013; 31 Suppl 2:B209-15. PMC: 3919153. DOI: 10.1016/j.vaccine.2012.11.106. View

Sato Y, Roman M, Tighe H, Lee D, Corr M, Nguyen M . Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science. 1996; 273(5273):352-4. DOI: 10.1126/science.273.5273.352. View

Hancock G, Heers K, Smith J, Scheuer C, Ibraghimov A, Pryharski K . CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV). Vaccine. 2001; 19(32):4874-82. DOI: 10.1016/s0264-410x(01)00228-6. View

10.

van Elden L, van Loon A, van der Beek A, Hendriksen K, Hoepelman A, van Kraaij M . Applicability of a real-time quantitative PCR assay for diagnosis of respiratory syncytial virus infection in immunocompromised adults. J Clin Microbiol. 2003; 41(9):4378-81. PMC: 193825. DOI: 10.1128/JCM.41.9.4378-4381.2003. View

11.

Krieg A, Wu T, Weeratna R, Efler S, Yang L, Yi A . Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci U S A. 1998; 95(21):12631-6. PMC: 22882. DOI: 10.1073/pnas.95.21.12631. View

12.

Kapikian A, Mitchell R, Chanock R, Shvedoff R, Stewart C . An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol. 1969; 89(4):405-21. DOI: 10.1093/oxfordjournals.aje.a120954. View

13.

Chin J, MAGOFFIN R, Shearer L, SCHIEBLE J, LENNETTE E . Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol. 1969; 89(4):449-63. DOI: 10.1093/oxfordjournals.aje.a120957. View

14.

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

15.

Lee H, Choi E, Lee K, Kim H, Na B, Kwon M . Oral Administration of p-Hydroxycinnamic Acid Attenuates Atopic Dermatitis by Downregulating Th1 and Th2 Cytokine Production and Keratinocyte Activation. PLoS One. 2016; 11(3):e0150952. PMC: 4784746. DOI: 10.1371/journal.pone.0150952. View

16.

Techaarpornkul S, Barretto N, Peeples M . Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene. J Virol. 2001; 75(15):6825-34. PMC: 114409. DOI: 10.1128/JVI.75.15.6825-6834.2001. View

17.

Ulmer J, Wahren B, Liu M . Gene-based vaccines: recent technical and clinical advances. Trends Mol Med. 2006; 12(5):216-22. DOI: 10.1016/j.molmed.2006.03.007. View

18.

Tayyari F, Sutton T, Manson H, Hegele R . CpG-oligodeoxynucleotides inhibit RSV-enhanced allergic sensitisation in guinea pigs. Eur Respir J. 2005; 25(2):295-302. DOI: 10.1183/09031936.05.00016304. View

19.

Murphy B, Walsh E . Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol. 1988; 26(8):1595-7. PMC: 266671. DOI: 10.1128/jcm.26.8.1595-1597.1988. View

20.

Winer J, Jung C, Shackel I, Williams P . Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem. 1999; 270(1):41-9. DOI: 10.1006/abio.1999.4085. View